Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
RNAC Cartesian Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: RNAC
Price (delayed)
$9.54
Market cap
$247.6M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.1
Enterprise value
$81.24M
selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic
Highlights
The company's EPS has surged by 98% YoY and by 75% QoQ
RNAC's net income has soared by 85% YoY and by 51% from the previous quarter
RNAC's revenue is up by 32% year-on-year but it is down by 12% since the previous quarter
RNAC's gross profit is up by 32% YoY but it is down by 12% QoQ
The company's debt rose by 35% YoY
Key stats
What are the main financial stats of RNAC
Market
Valuations
Earnings
Shares outstanding
25.95M
Market cap
$247.6M
Enterprise value
$81.24M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
7.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.38
Revenue
$34.17M
Gross profit
$34.17M
Operating income
-$52.44M
Net income
-$38.31M
EBIT
-$38.02M
EBITDA
-$33.79M
Free cash flow
-$40.08M
Per share
Balance sheet
Liquidity
EPS
-$1.1
EPS diluted
-$1.15
Free cash flow per share
-$1.55
Book value per share
-$0.84
Revenue per share
$1.32
TBVPS
$13.94
Total assets
$409.13M
Total liabilities
$430.92M
Debt
$14.07M
Equity
-$21.79M
Working capital
$170.12M
Debt to equity
-0.65
Current ratio
12.34
Quick ratio
12.15
Net debt/EBITDA
4.92
Margins
Efficiency
Dividend
EBITDA margin
-98.9%
Gross margin
100%
Net margin
-112.1%
Operating margin
-153.4%
Return on assets
-10.3%
Return on equity
N/A
Return on invested capital
-20.9%
Return on capital employed
-9.6%
Return on sales
-111.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RNAC stock price
How has the Cartesian Therapeutics stock price performed over time
Intraday
-3.64%
1 week
4.95%
1 month
-24.88%
1 year
-73.33%
YTD
-46.73%
QTD
-27.62%
Financial performance
How have Cartesian Therapeutics's revenue and profit performed over time
Revenue
$34.17M
Gross profit
$34.17M
Operating income
-$52.44M
Net income
-$38.31M
Gross margin
100%
Net margin
-112.1%
The company's net margin has surged by 89% YoY and by 44% QoQ
RNAC's net income has soared by 85% YoY and by 51% from the previous quarter
RNAC's operating margin has soared by 51% YoY but it is down by 36% from the previous quarter
The operating income has increased by 36% YoY but it has decreased by 19% QoQ
Price vs fundamentals
How does RNAC's price correlate with its fundamentals
Growth
What is Cartesian Therapeutics's growth rate over time
Valuation
What is Cartesian Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
7.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.38
The company's EPS has surged by 98% YoY and by 75% QoQ
The company's equity has surged by 81% YoY
RNAC's revenue is up by 32% year-on-year but it is down by 12% since the previous quarter
RNAC's P/S is 21% lower than its 5-year quarterly average of 9.1 and 14% lower than its last 4 quarters average of 8.4
Efficiency
How efficient is Cartesian Therapeutics business performance
Cartesian Therapeutics's ROIC has soared by 94% YoY and by 53% from the previous quarter
The return on assets has surged by 91% year-on-year and by 48% since the previous quarter
The company's return on sales has surged by 89% YoY and by 44% QoQ
Dividends
What is RNAC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RNAC.
Financial health
How did Cartesian Therapeutics financials performed over time
Cartesian Therapeutics's total assets is 5% less than its total liabilities
The quick ratio is up by 31% QoQ
RNAC's current ratio is up by 31% QoQ
The company's debt is 165% higher than its equity
The company's equity has surged by 81% YoY
Cartesian Therapeutics's debt to equity has soared by 68% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.